title: The efficacy of amlodipine in myocardial ischemia.
abstract: Calcium antagonists are among the most potent and efficacious drugs used in the treatment of angina pectoris. Amlodipine, a new member of this family of dihydropyridines, has a unique pharmacokinetic profile with high bioavailability and an extended period of pharmacodynamic activity. In formal randomized, double-blind, placebo-controlled trials with exercise tests carried out 24 hours after administration, amlodipine was significantly more effective than the placebo and comparable in efficacy with the calcium antagonist diltiazem and the beta-blocking drug nadolol. In addition to extending exercise capacity in patients with angina pectoris, amlodipine significantly reduces ECG evidence of myocardial ischemia. Amlodipine has also been found to be effective in reducing the anginal attack rate in patients with vasospastic angina. From the evidence available, it is concluded that once-daily treatment with amlodipine in the dose range of 5 to 10 mg is effective in improving exercise capacity and reducing anginal attack rate in patients with chronic stable angina pectoris and also those with vasospastic angina.
authors.affiliation: Department of Medical Cardiology, General Infirmary at Leeds, England.
authors.forename: S H
authors.initials: SH
authors.lastname: Taylor
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D017311:Amlodipine; D000787:Angina Pectoris / Q000188:drug therapy; D000788:Angina Pectoris, Variant / Q000188:drug therapy; D002121:Calcium Channel Blockers; D003327:Coronary Disease / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D009543:Nifedipine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D017311:Amlodipine; D009543:Nifedipine